Based on the role of hypoxia-associated molecules in cancer cell biological behaviour and clinical outcome, we assumed there might be an association, at the genetic and protein level, between HIF1A, LOX, CA9 and KDR genetic variants, the protein expression and prostate carcinoma. The gene discussed is LOX; the disease is cancer.